Wall Street rebounds as Treasury yields fall; Moderna soars on the back of its melanoma vaccine - Il Sole 24 ORE

Wall Street staged a rebound as Treasury yields pulled back from recent highs, easing pressure on equities. Falling yields typically reduce the discount rate applied to future corporate earnings, making stocks more attractive relative to bonds. The move suggests investors are recalibrating their expectations for interest rates and inflation, with the bond market acting as a key barometer for risk appetite.

In the same session, Moderna shares surged following positive developments around its experimental melanoma vaccine. The therapy, developed in partnership with Merck, is designed to be personalized to each patient's tumor and has shown promise in earlier-stage trials. For Moderna, success would broaden its pipeline beyond COVID-19 and open a new frontier in oncology—though regulatory hurdles and large-scale trial results remain pending.

Looking ahead, market participants will watch whether Treasury yields stabilize and how durable the equity rebound proves. For biotech, the focus stays on upcoming efficacy data and regulatory timelines. Neither the path of rates nor vaccine approval can be forecast with certainty, but both will likely drive sector-specific moves in the weeks ahead.